Long Term Safety and Efficacy of Abatacept in Patients with Rheumatoid Arthritis

Chang-Keun Lee

doi:10.4078/jrd.2013.20.2.71

Journal List > J Rheum Dis > v.20(2) > 1064095

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: Long Term Safety and Efficacy of Abatacept in Patients with Rheumatoid Arthritis

Editorial

J Rheum Dis 2013;20(2):71-73.

Published online: 31 April 2013

DOI: https://doi.org/10.4078/jrd.2013.20.2.71

Long Term Safety and Efficacy of Abatacept in Patients with Rheumatoid Arthritis

Chang-Keun Lee

Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Corresponding to : Chang-Keun Lee, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. E-mail : cklee@amc.seoul.kr

Received 1 April 2013 Accepted 8 April 2013

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Korhonen R, Moilanen E. Abatacept, a novel CD80/86- CD28 T cell costimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009; 104:276–84.

2. Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev. 2008; 8:76–82.

3. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009; 27:907–13.

4. Kushnir M, Ashurova A, Shriky R, Swearingen C, Yazici Y. Infliximab, abatacept and rituximab use in the treatment of rheumatoid arthritis in the real world: view from the infusion unit. Ann Rheum Dis. 2010; 69(Suppl 3):675.

5. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, re-activity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A. 2000; 97:12711–6.

6. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995; 96:987–93.

7. Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L, Juárez-Reyes A, Monsiváis-Urenda A, Baranda L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol. 2011; 31:588–95.

8. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008; 67:1603–9.

9. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody- dependent cellular cytotoxicity. J Rheumatol. 2007; 34:2204–10.

10. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144:865–76.

11. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008; 67:1096–103.

12. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353:1114–23.

13. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009; 68:1870–7.

14. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane over-view. Cochrane Database Syst Rev. 2011; CD008794.

15. Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritisreceiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009; 36:736–42.

16. Genovese M, Schiff M, Luggen ME, Le Bars M, Becker JC, Aranda R, et al. Safety, efficacy and health-related quality of life (HRQoL) through 5 years of abatacept (ABA) treatment in patients with rheumatoid arthritis (RA) and an inadequate response to anti-tumour necrosis factor (TNF) therapy. Ann Rheum Dis. 2010; 69(Suppl 3):385.

17. Shim SC, Park SH, Bae SC, Choe JY, Song YW, Mitra P, et al. Longterm safety and efficacy of abatacept in kore-ans with rheumatoid arthritis. J Rheum Dis. 2013; 20:30–9.

18. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013; 65:28–38.

19. Keystone E. Recent concepts in the inhibition of radio-graphic progression with biologics. Curr Opin Rheumatol. 2009; 21:231–7.

TOOLS

Similar articles